Advances in biomarkers for immunotherapy in small-cell lung cancer

Advances in biomarkers for immunotherapy in small-cell lung cancer

Small-cell lung cancer (SCLC) is a refractory cancer with rapid growth and high aggressiveness. Extensive-stage SCLC is initially sensitive to chemotherapy; however, drug resistance and recurrence occur rapidly, resulting in a poor survival outcome due to lack of subsequently efficient therapy. The...

Full description

Bibliographic Details
Main Authors: Hui Li, Peiyan Zhao, Lin Tian, Yuanhua Lu, Xinyue Wang, Wenjun Shao, Ying Cheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Immunology
Subjects:
small-cell lung cancer
immunotherapy
biomarker
research advances
predictive
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1490590/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1490590/full

Similar Items